Postbiotic-enabled targeting of the host-microbiota-pathogen interface: Hints of antibiotic decline?

Pharmaceutics

Volumn 12, Issue 7, 2020, Pages 1-30

  Puccetti, Matteo ^a   Xiroudaki, Styliani ^a   Ricci, Maurizio ^a   Giovagnoli, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

3 indole carboxaldehyde; Antimicrobial resistance; Host microbiota pathogen interface; Infectious diseases; Microbiota; Postbiotics; Tryptophan metabolites

Indexed keywords

ACETYLSALICYLIC ACID; AROMATIC HYDROCARBON RECEPTOR; ARYLBUTYRIC ACID DERIVATIVE; CALCITRIOL; CARNITINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FARNESOID X RECEPTOR; FINGOLIMOD; GAMMA INTERFERON; GLIBENCLAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBUPROFEN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 22; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINIC ACID; PREBIOTIC AGENT; PREDNISONE; PREGNANE X RECEPTOR; PROBIOTIC AGENT; RETINOIC ACID; TAURINE; UNINDEXED DRUG; VERAPAMIL;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ATOPIC DERMATITIS; BACTERIAL VIRULENCE; BACTERIOPHAGE; CARBOHYDRATE METABOLISM; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL POPULATION; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DRUG REPOSITIONING; FECAL MICROBIOTA TRANSPLANTATION; HOMEOSTASIS; HOST MICROBE INTERACTION; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; INTESTINE FLORA; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MOLECULAR INTERACTION; NONHUMAN; QUORUM SENSING; REGULATORY MECHANISM; REVIEW; TH1 CELL; TH2 CELL; TUBERCULOSIS;

EID: 85088891286     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics12070624     Document Type: Review

References (292)

1. Amann, S.; Neef, K.; Kohl, S. Antimicrobial resistance (AMR). Eur. J. Hosp. Pharm. 2019, 26, 175–177. 2. Tacconelli, E.; Sifakis, F.; Harbarth, S.; Schrijver, R.; van Mourik, M.; Voss, A.; Sharland, M.; Rajendran, N.B.; Rodríguez-Baño, J.; Bielicki, J.; et al. Surveillance for control of antimicrobial resistance. Lancet Infect. Dis. 2018, 18, e99–e106.
2. Jacob, J.T.; Klein, E.; Laxminarayan, R.; Beldavs, Z.; Lynfield, R.; Kallen, A.J.; Ricks, P.; Edwards, J.; Srinivasan, A.; Fridkin, S.; et al. Vital signs: Carbapenem-resistant enterobacteriaceae. Morb. Mortal. Wkly. Rep. 2013, 62, 165–169.
3. Spellberg, B.; Gilbert, D.N. The Future of Antibiotics and Resistance: A Tribute to a Career of Leadership by John Bartlett. Clin. Infect. Dis. 2014, 59, S71–S75.
4. WHO, W.H.O. Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2020; Geneva, 2020;
5. Spellberg, B.; Bartlett, J.G.; Gilbert, D.N. The future of antibiotics and resistance. N. Engl. J. Med. 2013, 368, 299–302.
6. Gould, I.M.; Bal, A.M. New antibiotic agents in the pipeline and how hey can help overcome microbial resistance. Virulence 2013, 4, 185–191.
7. Murray, A.K. The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial Resistance. Front. Microbiol. 2020, 11, 1–4.
8. AMR Industry Alliance 2020 Progress Report. 2020,://www.amrindustryalliance.org/wp-content/uploads/2020/01/AMR-2020-Progress-Report.pdf (accessed on 25 June 2020).
9. Wang, W.; Arshad, M.I.; Khurshid, M.; Rasool, M.H.; Nisar, M.A.; Aslam, M.A.; Qamar, M.U. Antibiotic resistance: a rundown of a global crisis. Infect. Drug Resist. 2018, 1645–1658.
10. Martens, E.; Demain, A.L. The antibiotic resistance crisis, with a focus on the United States. J. Antibiot. (Tokyo). 2017, 70, 520–526.
11. The Lancet The antimicrobial crisis: enough advocacy, more action. Lancet 2020, 395, 247.
12. Lee Ventola, C. The antibiotic resistance crisis: Part 2: Management strategies and new agents. P T 2015, 40, 344–352.
13. Ventola, C.L. The antibiotic resistance crisis: causes and threats. P T J. 2015.
14. Modi, S.R.; Collins, J.J.; Relman, D.A. Antibiotics and the gut microbiota. J. Clin. Invest. 2014, 124, 4212– 4218.
15. Paul, D.; Manna, S.; Mandal, S.M. Antibiotics Associated Disorders and Post-biotics Induced Rescue in Gut Health. Curr. Pharm. Des. 2017, 24, 821–829.
16. Grigg, J.B.; Sonnenberg, G.F. Host-Microbiota Interactions Shape Local and Systemic Inflammatory Diseases. J. Immunol. 2017, 198, 564–571.
17. Li, X. V.; Leonardi, I.; Iliev, I.D. Gut Mycobiota in Immunity and Inflammatory Disease. Immunity 2019, 50, 1365–1379.
18. Francino, M.P. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front. Microbiol. 2016, 6.
19. Chan, B.K.; Abedon, S.T.; Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013, 8, 769–783.
20. Tagliabue, A.; Rappuoli, R. Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. Front. Immunol. 2018, 9.
21. Abedon, S.T. Phage therapy of pulmonary infections. Bacteriophage 2015, 5, e1020260.
22. Yasuyuki, M.; Kunihiro, K.; Kurissery, S.; Kanavillil, N.; Sato, Y.; Kikuchi, Y. Antibacterial properties of nine pure metals: A laboratory study using Staphylococcus aureus and Escherichia coli. Biofouling 2010, 26, 851–858.
23. Beloin, C.; Renard, S.; Ghigo, J.-M.; Lebeaux, D. Novel approaches to combat bacterial biofilms. Curr. Opin. Pharmacol. 2014, 18, 61–68.
24. Krachler, A.M.; Orth, K. Targeting the bacteria-host interface strategies in anti-adhesion therapy. Virulence 2013, 4, 284–294.
25. DeFilipp, Z.; Bloom, P.P.; Soto, M.T.; Mansour, M.K.; Sater, M.R.A.; Huntley, M.H.; Turbett, S.; Chung, R.T.; Chen, Y. Bin; Hohmann, E.L. Drug-resistant e. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 2019, 381, 2043–2050.
26. Nielsen, T.B.; Brass, E.P.; Gilbert, D.N.; Bartlett, J.G.; Spellberg, B. Sustainable discovery and development of antibiotics-Is a nonprofit approach the future? N. Engl. J. Med. 2019, 381, 503–505.
27. Diel, R. Treatment of tuberculosis. Pneumologe 2019, 16, 117–130.
28. Kaufmann, S.H.E.; Dorhoi, A.; Hotchkiss, R.S.; Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 2018, 17, 35–56.
29. Andersson, J.A.; Sha, J.; Kirtley, M.L.; Reyes, E.; Fitts, E.C.; Dann, S.M.; Chopra, A.K. Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics. Antimicrob. Agents Chemother. 2017, 62.
30. Terme, M.; Ullrich, E.; Delahaye, N.F.; Chaput, N.; Zitvogel, L. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nat. Immunol. 2008, 9, 486–494.
31. Ulevitch, R.J. Therapeutics targeting the innate immune system. Nat. Rev. Immunol. 2004, 4, 512–520.
32. Montoya, D.; Inkeles, M.S.; Liu, P.T.; Realegeno, S.; B. Teles, R.M.; Vaidya, P.; Munoz, M.A.; Schenk, M.; Swindell, W.R.; Chun, R.; et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci. Transl. Med. 2014, 6, 250ra114-250ra114.
33. Wallis, R.S.; van Vuuren, C.; Potgieter, S. Adalimumab Treatment of Life‐Threatening Tuberculosis. Clin. Infect. Dis. 2009, 48, 1429–1432.
34. Phillips, B.L.; Mehra, S.; Ahsan, M.H.; Selman, M.; Khader, S.A.; Kaushal, D. LAG3 Expression in Active Mycobacterium tuberculosis Infections. Am. J. Pathol. 2015, 185, 820–833.
35. Skrahin, A.; Ahmed, R.K.; Ferrara, G.; Rane, L.; Poiret, T.; Isaikina, Y.; Skrahina, A.; Zumla, A.; Maeurer, M.J. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir. Med. 2014, 2, 108– 122. 37. Paik, S.; Kim, J.K.; Chung, C.; Jo, E.K. Autophagy: A new strategy for host-directed therapy of tuberculosis. Virulence 2019, 10, 448–459.
36. Atkin, T.A.; Maher, C.M.; Gerlach, A.C.; Gay, B.C.; Antonio, B.M.; Santos, S.C.; Padilla, K.M.; Rader, J.A.; Krafte, D.S.; Fox, M.A.; et al. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy. Epilepsia 2018, 59, 802–813.
37. Tharmalingam, N.; Port, J.; Castillo, D.; Mylonakis, E. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Sci. Rep. 2018, 8, 1–12.
38. Abdelaleem, M.; Ezzat, H.; Osama, M.; Megahed, A.; Alaa, W.; Gaber, A.; Shafei, A.; Refaat, A. Prospects for repurposing CNS drugs for cancer treatment. Oncol. Rev. 2019, 13, 37–42.
39. Tobin, D.M.; Roca, F.J.; Ray, J.P.; Ko, D.C.; Ramakrishnan, L. An Enzyme That Inactivates the Inflammatory Mediator Leukotriene B4 Restricts Mycobacterial Infection. PLoS One 2013, 8, e67828.
40. Vilaplana, C.; Marzo, E.; Tapia, G.; Diaz, J.; Garcia, V.; Cardona, P.J. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 2013, 208, 199–202.
41. Ivanyi, J.; Zumla, A. Nonsteroidal Antiinflammatory Drugs for Adjunctive Tuberculosis Treatment. J. Infect. Dis. 2013, 208, 185–188.
42. Blum, C.A.; Nigro, N.; Briel, M.; Schuetz, P.; Ullmer, E.; Suter-Widmer, I.; Winzeler, B.; Bingisser, R.; Elsaesser, H.; Drozdov, D.; et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015, 385, 1511– 1518.
43. Ferrer, M.; Torres, A.; Baer, R.; Hernández, C.; Roca, J.; Rodriguez-Roisin, R. Effect of Acetylsalicylic Acid on Pulmonary Gas Exchange in Patients With Severe Pneumonia. Chest 1997, 111, 1094–1100.
44. Bernard, G.R.; Wheeler, A.P.; Russell, J.A.; Schein, R.; Summer, W.R.; Steinberg, K.P.; Fulkerson, W.J.; Wright, P.E.; Christman, B.W.; Dupont, W.D.; et al. The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis. N. Engl. J. Med. 1997, 336, 912–918.
45. Halperin, S.A.; Vaudry, W.; Boucher, F.D.; Mackintosh, K.; Waggener, T.B.; Smith, B. Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatr. Infect. Dis. J. 2007, 26, 79–81.
46. Bruss, J.B.; Siber, G.R. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin. Diagn. Lab. Immunol. 1999, 6, 464–470.
47. Scanlon, K.M.; Skerry, C.; Carbonetti, N.H. Novel therapies for the treatment of pertussis disease. Pathog. Dis. 2015, 73, ftv074.
48. Koh, G.C.K.W.; Weehuizen, T.A.; Breitbach, K.; Krause, K.; de Jong, H.K.; Kager, L.M.; Hoogendijk, A.J.; Bast, A.; Peacock, S.J.; van der Poll, T.; et al. Glyburide Reduces Bacterial Dissemination in a Mouse Model of Melioidosis. PLoS Negl. Trop. Dis. 2013, 7, e2500.
49. Skerry, C.; Scanlon, K.; Rosen, H.; Carbonetti, N.H. Sphingosine-1-phosphate Receptor Agonism Reduces Bordetella pertussis– mediated Lung Pathology. J. Infect. Dis. 2015, 211, 1883–1886.
50. Döcke, W.D.; Randow, F.; Syrbe, U.; Krausch, D.; Asadullah, K.; Reinke, P.; Volk, H.D.; Kox, W. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment. Nat. Med. 1997, 3, 678–681.
51. Rosenbloom, A.J.; Linden, P.K.; Dorrance, A.; Penkosky, N.; Cohen-Melamed, M.H.; Pinsky, M.R. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005, 127, 2139–2150.
52. Presneill, J.J.; Harris, T.; Stewart, A.G.; Cade, J.F.; Wilson, J.W. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 2002, 166, 138–143.
53. Steinmann, J.; Halldórsson, S.; Agerberth, B.; Gudmundsson, G.H. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob. Agents Chemother. 2009, 53, 5127–5133.
54. Wang, T.-T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S.; et al. Cutting Edge: 1,25-Dihydroxyvitamin D 3 Is a Direct Inducer of Antimicrobial Peptide Gene Expression. J. Immunol. 2004, 173, 2909–2912.
55. Gombart, A.F.; Borregaard, N.; Koeffler, H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D 3. FASEB J. 2005, 19, 1067–1077.
56. Sechet, E.; Telford, E.; Bonamy, C.; Sansonetti, P.J.; Sperandio, B. Natural molecules induce and synergize to boost expression of the human antimicrobial peptide β-defensin-3. Proc. Natl. Acad. Sci. U. S. A. 2018, 115, E9869–E9878.
57. Barber, D.L.; Sakai, S.; Kudchadkar, R.R.; Fling, S.P.; Day, T.A.; Vergara, J.A.; Ashkin, D.; Cheng, J.H.; Lundgren, L.M.; Raabe, V.N.; et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci. Transl. Med. 2019, 11.
58. Munguia, J.; Nizet, V. Pharmacological Targeting of the Host–Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs. Trends Pharmacol. Sci. 2017, 38, 473–488.
59. Roduit, C.; Scholtens, S.; De Jongste, J.C.; Wijga, A.H.; Gerritsen, J.; Postma, D.S.; Brunekreef, B.; Hoekstra, M.O.; Aalberse, R.; Smit, H.A. Asthma at 8 years of age in children born by caesarean section. Thorax 2009, 64, 107–113.
60. Mårild, K.; Ye, W.; Lebwohl, B.; Green, P.H.R.; Blaser, M.J.; Card, T.; Ludvigsson, J.F. Antibiotic exposure and the development of coeliac disease: a nationwide case–control study. BMC Gastroenterol. 2013, 13, 109.
61. Watson, J.; Jones, R.C.; Cortes, C.; Gerber, S.I.; Golash, R.G.; Price, J.; Bancroft, E.; Mascola, L.; Gorwitz, R.J.; Jernigan, D.B.; et al. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns-Chicago and Los Angeles County, 2004. Morb. Mortal. Wkly. Rep. 2006, 55, 329– 332.
62. Sekirov, I.; Tam, N.M.; Jogova, M.; Robertson, M.L.; Li, Y.; Lupp, C.; Finlay, B.B. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect. Immun. 2008, 76, 4726–4736.
63. Chang, J.Y.; Antonopoulos, D.A.; Kalra, A.; Tonelli, A.; Khalife, W.T.; Schmidt, T.M.; Young, V.B. Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile –Associated Diarrhea. J. Infect. Dis. 2008, 197, 435–438.
64. Buffie, C.G.; Jarchum, I.; Equinda, M.; Lipuma, L.; Gobourne, A.; Viale, A.; Ubeda, C.; Xavier, J.; Pamer, E.G. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 2012, 80, 62–73.
65. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 2012, 148, 1258–1270.
66. Fessler, J.; Matson, V.; Gajewski, T.F. Exploring the emerging role of the microbiome in cancer immunotherapy. J. Immunother. Cancer 2019, 7, 108. 69. Taylor, V.H. The microbiome and mental health: Hope or hype? J. Psychiatry Neurosci. 2019, 44, 219–222. 70. Thaiss, C.A.; Elinav, E. The remedy within: will the microbiome fulfill its therapeutic promise? J. Mol. Med. 2017, 95, 1021–1027.
67. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207–14.
68. Simon, G.L.; Gorbach, S.L. Intestinal flora in health and disease. Gastroenterology 1984, 86, 174–193.
69. Delhaes, L.; Monchy, S.; Fréalle, E.; Hubans, C.; Salleron, J.; Leroy, S.; Prevotat, A.; Wallet, F.; Wallaert, B.; Dei-Cas, E.; et al. The Airway Microbiota in Cystic Fibrosis: A Complex Fungal and Bacterial Community—Implications for Therapeutic Management. PLoS One 2012, 7, e36313.
70. Ott, S.J.; Kühbacher, T.; Musfeldt, M.; Rosenstiel, P.; Hellmig, S.; Rehman, A.; Drews, O.; Weichert, W.; Timmis, K.N.; Schreiber, S. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand. J. Gastroenterol. 2008, 43, 831–841.
71. Li, Q.; Wang, C.; Tang, C.; He, Q.; Li, N.; Li, J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in crohn’s disease. J. Clin. Gastroenterol. 2014, 48, 513–523.
72. Hoffmann, C.; Dollive, S.; Grunberg, S.; Chen, J.; Li, H.; Wu, G.D.; Lewis, J.D.; Bushman, F.D. Archaea and Fungi of the Human Gut Microbiome: Correlations with Diet and Bacterial Residents. PLoS One 2013, 8, e66019.
73. Zhang, E.; Tanaka, T.; Tajima, M.; Tsuboi, R.; Nishikawa, A.; Sugita, T. Characterization of the skin fungal microbiota in patients with atopic dermatitis and in healthy subjects. Microbiol. Immunol. 2011, 55, 625– 632.
74. Smeekens, S.P.; Malireddi, R.K.; Plantinga, T.S.; Buffen, K.; Oosting, M.; Joosten, L.A.B.; Kullberg, B.J.; Perfect, J.R.; Scott, W.K.; Van De Veerdonk, F.L.; et al. Autophagy is redundant for the host defense against systemic Candida albicans infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 711–722.
75. Cully, M. Antibiotics alter the gut microbiome and host health. Nat. Milestones 2019, 1423, S19.
76. Lavelle, A.; Hoffmann, T.W.; Pham, H.P.; Langella, P.; Guédon, E.; Sokol, H. Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. Microbiome 2019, 7, 111.
77. Bhalodi, A.A.; Van Engelen, T.S.R.; Virk, H.S.; Wiersinga, W.J. Impact of antimicrobial therapy on the gut microbiome. J. Antimicrob. Chemother. 2019, 74, I6–I15.
78. Baümler, A.J.; Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016, 535, 85–93.
79. Becattini, S.; Taur, Y.; Pamer, E.G. Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol. Med. 2016, 22, 458–478. 84. Zhang, S.; Chen, D.C.; Chen, L.M. Facing a new challenge: The adverse effects of antibiotics on gut microbiota and host immunity. Chin. Med. J. (Engl). 2019, 132, 1135–1138.
80. Guarner, F.; Malagelada, J.R. Gut flora in health and disease. Lancet 2003, 361, 512–519.
81. Stefka, A.T.; Feehley, T.; Tripathi, P.; Qiu, J.; McCoy, K.; Mazmanian, S.K.; Tjota, M.Y.; Seo, G.Y.; Cao, S.; Theriault, B.R.; et al. Commensal bacteria protect against food allergen sensitization. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 13145–13150.
82. Hsiao, E.Y.; McBride, S.W.; Hsien, S.; Sharon, G.; Hyde, E.R.; McCue, T.; Codelli, J.A.; Chow, J.; Reisman, S.E.; Petrosino, J.F.; et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013, 155, 1451–1463.
83. Teo, S.M.; Mok, D.; Pham, K.; Kusel, M.; Serralha, M.; Troy, N.; Holt, B.J.; Hales, B.J.; Walker, M.L.; Hollams, E.; et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe 2015, 17, 704–715.
84. Cuthbertson, L.; Rogers, G.B.; Walker, A.W.; Oliver, A.; Green, L.E.; Daniels, T.W.V.; Carroll, M.P.; Parkhill, J.; Bruce, K.D.; Van Der Gast, C.J. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J. 2016, 10, 1081–1091.
85. Dedrick, R.M.; Guerrero-Bustamante, C.A.; Garlena, R.A.; Russell, D.A.; Ford, K.; Harris, K.; Gilmour, K.C.; Soothill, J.; Jacobs-Sera, D.; Schooley, R.T.; et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 2019, 25, 730–733.
86. Chan, B.K.; Turner, P.E.; Kim, S.; Mojibian, H.R.; Elefteriades, J.A.; Narayan, D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol. Med. Public Heal. 2018, 2018, 60–66.
87. Jault, P.; Leclerc, T.; Jennes, S.; Pirnay, J.P.; Que, Y.A.; Resch, G.; Rousseau, A.F.; Ravat, F.; Carsin, H.; Le Floch, R.; et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 2019, 19, 35–45.
88. Vahedi, A.; Soltan Dallal, M.M.; Douraghi, M.; Nikkhahi, F.; Rajabi, Z.; Yousefi, M.; Mousavi, M. Isolation and identification of specific bacteriophage against enteropathogenic Escherichia coli (EPEC) and in vitro and in vivo characterization of bacteriophage. FEMS Microbiol. Lett. 2018, 365.
89. Chadha, P.; Katare, O.P.; Chhibber, S. Liposome loaded phage cocktail: Enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns 2017, 43, 1532–1543.
90. Murphy, C.L.; Zulquernain, S.A.; Shanahan, F. Faecal Microbiota Transplantation (FMT)-classical bedside-to-bench clinical research. QJM Volume 112, 2019.
91. Paramsothy, S.; Kamm, M.A.; Kaakoush, N.O.; Walsh, A.J.; van den Bogaerde, J.; Samuel, D.; Leong, R.W.L.; Connor, S.; Ng, W.; Paramsothy, R.; et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017, 389, 1218–1228.
92. Paramsothy, S.; Paramsothy, R.; Rubin, D.T.; Kamm, M.A.; Kaakoush, N.O.; Mitchell, H.M.; Castaño-Rodríguez, N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J. Crohn’s Colitis 2017, 11, 1180–1199.
93. Islam, S.U. Clinical Uses of Probiotics. Medicine (Baltimore). 2016, 95, e2658.
94. Kim, H.G.; Lee, S.Y.; Kim, N.R.; Lee, H.Y.; Ko, M.Y.; Jung, B.J.; Kim, C.M.; Lee, J.M.; Park, J.H.; Han, S.H.; et al. Lactobacillus plantarum lipoteichoic acid down-regulated Shigella flexneri peptidoglycan-induced inflammation. Mol. Immunol. 2011, 48, 382–391.
95. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humaran, L.G.; Gratadoux, J.-J.; Blugeon, S.; Bridonneau, C.; Furet, J.-P.; Corthier, G.; et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. 2008, 105, 16731–16736.
96. Hart, A.L.; Stagg, A.J.; Kamm, M.A. Use of Probiotics in the Treatment of Inflammatory Bowel Disease. J. Clin. Gastroenterol. 2003, 36, 111–119.
97. Stripling, J.; Kumar, R.; Baddley, J.W.; Nellore, A.; Dixon, P.; Howard, D.; Ptacek, T.; Lefkowitz, E.J.; Tallaj, J.A.; Benjamin, W.H.; et al. Loss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient With Clostridium difficile Colitis After Fecal Microbiota Transplant. Open Forum Infect. Dis. 2015, 2.
98. Cammarota, G.; Masucci, L.; Ianiro, G.; Bibbò, S.; Dinoi, G.; Costamagna, G.; Sanguinetti, M.; Gasbarrini, A. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 2015, 41, 835–843.
99. Battipaglia, G.; Malard, F.; Rubio, M.T.; Ruggeri, A.; Mamez, A.C.; Brissot, E.; Giannotti, F.; Dulery, R.; Joly, A.C.; Baylatry, M.T.; et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica 2019, 104, 1682–1688. 105. Ganeshan, S.D.; Hosseinidoust, Z. Phage therapy with a focus on the human microbiota. Antibiotics 2019.
100. Sutton, T.D.S.; Hill, C. Gut Bacteriophage: Current Understanding and Challenges. Front. Endocrinol. (Lausanne). 2019.
101. Hsu, B.B.; Gibson, T.E.; Yeliseyev, V.; Liu, Q.; Lyon, L.; Bry, L.; Silver, P.A.; Gerber, G.K. Dynamic Modulation of the Gut Microbiota and Metabolome by Bacteriophages in a Mouse Model. Cell Host Microbe 2019, 25, 803-814.e5.
102. Paule, A.; Frezza, D.; Edeas, M. Microbiota and Phage Therapy: Future Challenges in Medicine. Med. Sci. 2018.
103. Sausset, R.; Petit, M.A.; Gaboriau-Routhiau, V.; De Paepe, M. New insights into intestinal phages. Mucosal Immunol. 2020.
104. Wong, W.F.; Santiago, M. Microbial approaches for targeting antibiotic-resistant bacteria. Microb. Biotechnol. 2017, 10, 1047–1053.
105. Tkhilaishvili, T.; Lombardi, L.; Klatt, A.B.; Trampuz, A.; Di Luca, M. Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus. Int. J. Antimicrob. Agents 2018, 52, 842–853.
106. Fong, S.A.; Drilling, A.; Morales, S.; Cornet, M.E.; Woodworth, B.A.; Fokkens, W.J.; Psaltis, A.J.; Vreugde, S.; Wormald, P.-J. Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Front. Cell. Infect. Microbiol. 2017, 7.
107. Bourdin, G.; Navarro, A.; Sarker, S.A.; Pittet, A.-C.; Qadri, F.; Sultana, S.; Cravioto, A.; Talukder, K.A.; Reuteler, G.; Brüssow, H. Coverage of diarrhoea-associated E scherichia coli isolates from different origins with two types of phage cocktails. Microb. Biotechnol. 2014, 7, 165–176.
108. Maciejewska, B.; Olszak, T.; Drulis-Kawa, Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Appl. Microbiol. Biotechnol. 2018, 102, 2563–2581.
109. Furfaro, L.L.; Payne, M.S.; Chang, B.J. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles. Front. Cell. Infect. Microbiol. 2018, 8, 376. 116. Pirnay, J.P.; Verbeken, G.; Ceyssens, P.J.; Huys, I.; de Vos, D.; Ameloot, C.; Fauconnier, A. The magistral phage. Viruses 2018.
110. Lerner, A.; Matthias, T.; Aminov, R. Potential effects of horizontal gene exchange in the human gut. Front. Immunol. 2017, 8, 1630.
111. Wong, A.; Ngu, D.Y. Saint; Dan, L.A.; Ooi, A.; Lim, R.L.H. Detection of antibiotic resistance in probiotics of dietary supplements. Nutr. J. 2015, 14, 95.
112. Lerner, A.; Matthias, T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun. Rev. 2015, 14, 479–489.
113. Lerner, A.; Aminov, R.; Matthias, T. Transglutaminases in Dysbiosis As Potential Environmental Drivers of Autoimmunity. Front. Microbiol. 2017, 8.
114. Matthias, T.; Jeremias, P.; Neidhöfer, S.; Lerner, A. The industrial food additive, microbial transglutaminase, mimics tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmun. Rev. 2016, 15, 1111–1119.
115. Torsten, M.; Aaron, L. Microbial Transglutaminase Is Immunogenic and Potentially Pathogenic in Pediatric Celiac Disease. Front. Pediatr. 2018, 6.
116. Singh, A.; Sarangi, A.N.; Goel, A.; Srivastava, R.; Bhargava, R.; Gaur, P.; Aggarwal, A.; Aggarwal, R. Effect of administration of a probiotic preparation on gut microbiota and immune response in healthy women in India: an open-label, single-arm pilot study. BMC Gastroenterol. 2018, 18, 85.
117. Laursen, M.F.; Laursen, R.P.; Larnkjær, A.; Michaelsen, K.F.; Bahl, M.I.; Licht, T.R. Administration of two probiotic strains during early childhood does not affect the endogenous gut microbiota composition despite probiotic proliferation. BMC Microbiol. 2017, 17, 175.
118. Kristensen, N.B.; Bryrup, T.; Allin, K.H.; Nielsen, T.; Hansen, T.H.; Pedersen, O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016, 8, 52.
119. Muñoz, J.A.M.; Chenoll, E.; Casinos, B.; Bataller, E.; Ramón, D.; Genovés, S.; Montava, R.; Ribes, J.M.; Buesa, J.; Fàbrega, J.; et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl. Environ. Microbiol. 2011, 77, 8775–8783.
120. Jalali, M.; Abedi, D.; Varshosaz, J.; Najjarzadeh, M.; Mirlohi, M.; Tavakoli, N. Stability evaluation of freeze-dried Lactobacillus paracasei subsp. tolerance and Lactobacillus delbrueckii subsp. bulgaricus in oral capsules. Res. Pharm. Sci. 2012, 7, 31–36. 128. Markowiak, P.; Ślizewska, K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017, 9, 1021. 129. Pandey, K.R.; Naik, S.R.; Vakil, B. V. Probiotics, prebiotics and synbiotics-a review. J. Food Sci. Technol. 2015, 52, 7577–7587.
121. McFarland, L. V.; Goh, S. Are probiotics and prebiotics effective in the prevention of travellers’ diarrhea: A systematic review and meta-analysis. Travel Med. Infect. Dis. 2019, 27, 11–19.
122. Jin, L.; Deng, L.; Wu, W.; Wang, Z.; Shao, W.; Liu, J. Systematic review and meta-analysis of the effect of probiotic supplementation on functional constipation in children. Med. (United States) 2018, 97, e12174.
123. Rouhani, M.H.; Hadi, A.; Ghaedi, E.; Salehi, M.; Mahdavi, A.; Mohammadi, H. Do probiotics, prebiotics and synbiotics affect adiponectin and leptin in adults? A systematic review and meta-analysis of clinical trials. Clin. Nutr. 2019, 38, 2031–2037.
124. Tan-Lim, C.S.C.; Esteban-Ipac, N.A.R. Probiotics as treatment for food allergies among pediatric patients: a meta-analysis. World Allergy Organ. J. 2018, 11, 25.
125. Upadhyay, R.P.; Taneja, S.; Chowdhury, R.; Strand, T.A.; Bhandari, N. Effect of prebiotic and probiotic supplementation on neurodevelopment in preterm very low birth weight infants: findings from a meta-analysis. Pediatr. Res. 2018.
126. Aqaeinezhad Rudbane, S.M.; Rahmdel, S.; Abdollahzadeh, S.M.; Zare, M.; Bazrafshan, A.; Mazloomi, S.M. The efficacy of probiotic supplementation in rheumatoid arthritis: a meta-analysis of randomized, controlled trials. Inflammopharmacology 2018, 26, 67–76.
127. Hassan, H.; Rompola, M.; Glaser, A.W.; Kinsey, S.E.; Phillips, R.S. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support. Care Cancer 2018, 26, 2503–2509.
128. Vieira, A.T.; Fukumori, C.; Ferreira, C.M. New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin. Transl. Immunol. 2016, 5, e87.
129. Descamps, H.C.; Herrmann, B.; Wiredu, D.; Thaiss, C.A. The path toward using microbial metabolites as therapies. EBioMedicine 2019, 44, 747–754.
130. Klemashevich, C.; Wu, C.; Howsmon, D.; Alaniz, R.C.; Lee, K.; Jayaraman, A. Rational identification of diet-derived postbiotics for improving intestinal microbiota function. Curr. Opin. Biotechnol. 2014, 26, 85– 90.
131. Shoaie, S.; Ghaffari, P.; Kovatcheva-Datchary, P.; Mardinoglu, A.; Sen, P.; Pujos-Guillot, E.; De Wouters, T.; Juste, C.; Rizkalla, S.; Chilloux, J.; et al. Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome. Cell Metab. 2015, 22, 320–331.
132. Zeevi, D.; Korem, T.; Zmora, N.; Israeli, D.; Rothschild, D.; Weinberger, A.; Ben-Yacov, O.; Lador, D.; Avnit-Sagi, T.; Lotan-Pompan, M.; et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell 2015, 163, 1079–1094.
133. Umu, Ö.C.O.; Rudi, K.; Diep, D.B. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb. Ecol. Health Dis. 2017, 28, 1348886.
134. Wikoff, W.R.; Anfora, A.T.; Liu, J.; Schultz, P.G.; Lesley, S.A.; Peters, E.C.; Siuzdak, G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 3698–3703.
135. Zheng, X.; Xie, G.; Zhao, A.; Zhao, L.; Yao, C.; Chiu, N.H.L.; Zhou, Z.; Bao, Y.; Jia, W.; Nicholson, J.K.; et al. The footprints of gut microbial-mammalian co-metabolism. J. Proteome Res. 2011, 10, 5512–5522.
136. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009, 58, 1509–1517.
137. Rouse, M.; Singh, N.P.; Nagarkatti, P.S.; Nagarkatti, M. Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells. Br. J. Pharmacol. 2013, 169, 1305–1321.
138. Koeth, R.A.; Wang, Z.; Levison, B.S.; Buffa, J.A.; Org, E.; Sheehy, B.T.; Britt, E.B.; Fu, X.; Wu, Y.; Li, L.; et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, 576–585.
139. Wegh; Geerlings; Knol; Roeselers; Belzer Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond. Int. J. Mol. Sci. 2019, 20, 4673.
140. Aguilar-Toalá, J.E.; Garcia-Varela, R.; Garcia, H.S.; Mata-Haro, V.; González-Córdova, A.F.; Vallejo-Cordoba, B.; Hernández-Mendoza, A. Postbiotics: An evolving term within the functional foods field. Trends Food Sci. Technol. 2018, 75, 105–114.
141. Shenderov, B.A. Metabiotics: novel idea or natural development of probiotic conception. Microb. Ecol. Heal. Dis. 2013, 24.
142. Zhang, L.S.; Davies, S.S. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 2016, 8, 46.
143. Kho, Z.Y.; Lal, S.K. The Human Gut Microbiome-A Potential Controller of Wellness and Disease. Front. Microbiol. 2018, 9, 1835.
144. Zhang, Z.; Tang, H.; Chen, P.; Xie, H.; Tao, Y. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct. Target. Ther. 2019, 4, 41.
145. Donohoe, D.R.; Garge, N.; Zhang, X.; Sun, W.; O’Connell, T.M.; Bunger, M.K.; Bultman, S.J. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011, 13, 517–526.
146. Kaiko, G.E.; Ryu, S.H.; Koues, O.I.; Collins, P.L.; Solnica-Krezel, L.; Pearce, E.J.; Pearce, E.L.; Oltz, E.M.; Stappenbeck, T.S. The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. Cell 2016, 165, 1708–1720.
147. Round, J.L.; Mazmanian, S.K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. 2010, 107, 12204–12209.
148. Smith, P.M.; Howitt, M.R.; Panikov, N.; Michaud, M.; Gallini, C.A.; Bohlooly-Y, M.; Glickman, J.N.; Garrett, W.S. The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis. Science (80-.). 2013, 341, 569–573.
149. Atarashi, K.; Tanoue, T.; Shima, T.; Imaoka, A.; Kuwahara, T.; Momose, Y.; Cheng, G.; Yamasaki, S.; Saito, T.; Ohba, Y.; et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science (80-.). 2011, 331, 337–341.
150. Arpaia, N.; Green, J.A.; Moltedo, B.; Arvey, A.; Hemmers, S.; Yuan, S.; Treuting, P.M.; Rudensky, A.Y. A Distinct Function of Regulatory T Cells in Tissue Protection. Cell 2015, 162, 1078–1089.
151. Singh, N.; Gurav, A.; Sivaprakasam, S.; Brady, E.; Padia, R.; Shi, H.; Thangaraju, M.; Prasad, P.D.; Manicassamy, S.; Munn, D.H.; et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014, 40, 128–139.
152. Fukuda, S.; Toh, H.; Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping, D.L.; Suzuki, T.; et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469, 543–547.
153. Gaudier, E.; Jarry, A.; Blottière, H.M.; de Coppet, P.; Buisine, M.P.; Aubert, J.P.; Laboisse, C.; Cherbut, C.; Hoebler, C. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am. J. Physiol. Liver Physiol. 2004, 287, G1168–G1174.
154. Macia, L.; Tan, J.; Vieira, A.T.; Leach, K.; Stanley, D.; Luong, S.; Maruya, M.; Ian McKenzie, C.; Hijikata, A.; Wong, C.; et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 2015, 6, 6734.
155. Vinolo, M.A.R.; Rodrigues, H.G.; Hatanaka, E.; Sato, F.T.; Sampaio, S.C.; Curi, R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J. Nutr. Biochem. 2011, 22, 849–855.
156. Usami, M.; Kishimoto, K.; Ohata, A.; Miyoshi, M.; Aoyama, M.; Fueda, Y.; Kotani, J. Butyrate and trichostatin A attenuate nuclear factor κB activation and tumor necrosis factor α secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr. Res. 2008, 28, 321–328.
157. Chang, P. V.; Hao, L.; Offermanns, S.; Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. 2014, 111, 2247– 2252.
158. Singh, N.; Thangaraju, M.; Prasad, P.D.; Martin, P.M.; Lambert, N.A.; Boettger, T.; Offermanns, S.; Ganapathy, V. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J. Biol. Chem. 2010, 285, 27601–27608.
159. Trompette, A.; Gollwitzer, E.S.; Yadava, K.; Sichelstiel, A.K.; Sprenger, N.; Ngom-Bru, C.; Blanchard, C.; Junt, T.; Nicod, L.P.; Harris, N.L.; et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014, 20, 159–166.
160. Bakdash, G.; Vogelpoel, L.T.; van Capel, T.M.; Kapsenberg, M.L.; de Jong, E.C. Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells. Mucosal Immunol. 2015, 8, 265–278.
161. Zhang, Z.; Li, J.; Zheng, W.; Zhao, G.; Zhang, H.; Wang, X.; Guo, Y.; Qin, C.; Shi, Y. Peripheral Lymphoid Volume Expansion and Maintenance Are Controlled by Gut Microbiota via RALDH+ Dendritic Cells. Immunity 2016, 44, 330–342.
162. Mucida, D.; Park, Y.; Kim, G.; Turovskaya, O.; Scott, I.; Kronenberg, M.; Cheroutre, H. Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid. Science (80-.). 2007, 317, 256–260.
163. Hall, J.A.; Cannons, J.L.; Grainger, J.R.; Dos Santos, L.M.; Hand, T.W.; Naik, S.; Wohlfert, E.A.; Chou, D.B.; Oldenhove, G.; Robinson, M.; et al. Essential role for retinoic acid in the promotion of CD4+ T cell effector responses via retinoic acid receptor alpha. Immunity 2011, 34, 435–447. 173. Round, J.L.; Lee, S.M.; Li, J.; Tran, G.; Jabri, B.; Chatila, T.A.; Mazmanian, S.K. The Toll-Like Receptor 2 Pathway Establishes Colonization by a Commensal of the Human Microbiota. Science (80-.). 2011, 332, 974–977.
164. Mazmanian, S.K.; Round, J.L.; Kasper, D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453, 620–625.
165. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.; Bain, J.R.; et al. Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. Science (80-.). 2013, 341, 1241214–1241214.
166. Pols, T.W.H.; Nomura, M.; Harach, T.; Lo Sasso, G.; Oosterveer, M.H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.; et al. TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading. Cell Metab. 2011, 14, 747–757.
167. Devkota, S.; Wang, Y.; Musch, M.W.; Leone, V.; Fehlner-Peach, H.; Nadimpalli, A.; Antonopoulos, D.A.; Jabri, B.; Chang, E.B. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature 2012, 487, 104–108.
168. Levy, M.; Thaiss, C.A.; Zeevi, D.; Dohnalová, L.; Zilberman-Schapira, G.; Mahdi, J.A.; David, E.; Savidor, A.; Korem, T.; Herzig, Y.; et al. Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling. Cell 2015, 163, 1428–1443.
169. Zelante, T.; Iannitti, R.G.; Cunha, C.; DeLuca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D’Angelo, C.; Massi-Benedetti, C.; Fallarino, F.; et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013, 39, 372–385.
170. Qiu, J.; Heller, J.J.; Guo, X.; Chen, Z.E.; Fish, K.; Fu, Y.-X.; Zhou, L. The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid Cells. Immunity 2012, 36, 92–104.
171. Roager, H.M.; Dragsted, L.O. Diet-derived microbial metabolites in health and disease. Nutr. Bull. 2019, 44, 216–227.
172. Milligan, G.; Bolognini, D.; Sergeev, E. Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). Handb. Exp. Pharmacol. 2017, 236, 17–32.
173. Thaiss, C.A.; Zmora, N.; Levy, M.; Elinav, E. The microbiome and innate immunity. Nature 2016, 535, 65– 74.
174. Levin, A.D.; van den Brink, G.R. Selective inhibition of mucosal serotonin as treatment for IBD? Gut 2014, 63, 866–867.
175. Fiorucci, S.; Biagioli, M.; Zampella, A.; Distrutti, E. Bile Acids Activated Receptors Regulate Innate Immunity. Front. Immunol. 2018, 9, 1853.
176. Mertens, K.L.; Kalsbeek, A.; Soeters, M.R.; Eggink, H.M. Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. Front. Neurosci. 2017, 11.
177. Linsalata, M.; Giannini, R.; Notarnicola, M.; Cavallini, A. Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer. BMC Cancer 2006, 6, 191.
178. Ahern, G.P.; Wang, X.; Miyares, R.L. Polyamines are potent ligands for the capsaicin receptor TRPV1. J. Biol. Chem. 2006, 281, 8991–8995.
179. Zhang, M.; Wang, H.; Tracey, K.J. Regulation of macrophage activation and inflammation by spermine: A new chapter in an old story. Crit. Care Med. 2000, 28, N60–N66.
180. Fennema, D.; Phillips, I.R.; Shephard, E.A. Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. Drug Metab. Dispos. 2016, 44, 1839–1850.
181. Seldin, M.M.; Meng, Y.; Qi, H.; Zhu, W.; Wang, Z.; Hazen, S.L.; Lusis, A.J.; Shih, D.M. Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB. J. Am. Heart Assoc. 2016, 5.
182. Bae, E.-A.; Choo, M.-K.; Park, E.-K.; Park, S.-Y.; Shin, H.-Y.; Kim, D.-H. Metabolism of Ginsenoside Rc by Human Intestinal Bacteria and Its Related Antiallergic Activity. Biol. Pharm. Bull. 2002, 25, 743–747.
183. Stark, A.H.; Madar, Z. In vitro production of short-chain fatty acids by bacterial fermentation of dietary fiber compared with effects of those fibers on hepatic sterol synthesis in rats. J. Nutr. 1993, 123, 2166–73.
184. Macfarlane, S.; Macfarlane, G.T. Regulation of short-chain fatty acid production. Proc. Nutr. Soc. 2003, 62, 67–72.
185. Gérard, P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens 2013, 3, 14–24.
186. Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R.A.; Buell, G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (80-.). 1996, 272, 735–738.
187. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3, 543–553. 198. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 2002, 298, 714–719.
188. Roberts, E.; Golas, C.; Okey, A. Ah Receptor Mediating Induction of Aryl Hydrocarbon Hydroxylase: Detection in Human Lung by Binding of 2,3,7,8-[3H]Tetrachlorodibenzo–p-dioxin. Cancer Res. 1986, 46, 3739–3743.
189. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson, M.A.; Jones, S.A.; McKee, D.D.; Oliver, B.B.; Willson, T.M.; Zetterström, R.H.; et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92, 73–82.
190. Venkatesh, M.; Mukherjee, S.; Wang, H.; Li, H.; Sun, K.; Benechet, A.P.; Qiu, Z.; Maher, L.; Redinbo, M.R.; Phillips, R.S.; et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity 2014, 41, 296–310.
191. Holmes, E.; Loo, R.L.; Stamler, J.; Bictash, M.; Yap, I.K.S.; Chan, Q.; Ebbels, T.; De Iorio, M.; Brown, I.J.; Veselkov, K.A.; et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453, 396–400.
192. Smith, M.I.; Yatsunenko, T.; Manary, M.J.; Trehan, I.; Mkakosya, R.; Cheng, J.; Kau, A.L.; Rich, S.S.; Concannon, P.; Mychaleckyj, J.C.; et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (80-.). 2013, 339, 548–554.
193. Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J.; et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278, 11312– 11319.
194. Le Poul, E.; Loison, C.; Struyf, S.; Springael, J.Y.; Lannoy, V.; Decobecq, M.E.; Brezillon, S.; Dupriez, V.; Vassart, G.; Van Damme, J.; et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 2003, 278, 25481–25489.
195. Seljeset, S.; Siehler, S. Receptor-specific regulation of ERK1/2 activation by members of the “free fatty acid receptor” family. J. Recept. Signal Transduct. 2012, 32, 196–201.
196. Miyauchi, S.; Gopal, E.; Fei, Y.J.; Ganapathy, V. Functional Identification of SLC5A8, a Tumor Suppressor Down-regulated in Colon Cancer, as a Na+-coupled Transporter for Short-chain Fatty Acids. J. Biol. Chem. 2004, 279, 13293–13296.
197. Thangaraju, M.; Cresci, G.A.; Liu, K.; Ananth, S.; Gnanaprakasam, J.P.; Browning, D.D.; Mellinger, J.D.; Smith, S.B.; Digby, G.J.; Lambert, N.A.; et al. GPFM 09A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009, 69, 2826– 2832.
198. Steliou, K.; Boosalis, M.S.; Perrine, S.P.; Sangerman, J.; Faller, D. V. Butyrate histone deacetylase inhibitors. Biores. Open Access 2012, 1, 192–198.
199. Donohoe, D.R.; Collins, L.B.; Wali, A.; Bigler, R.; Sun, W.; Bultman, S.J. The Warburg Effect Dictates the Mechanism of Butyrate-Mediated Histone Acetylation and Cell Proliferation. Mol. Cell 2012, 48, 612–626.
200. Koh, A.; De Vadder, F.; Kovatcheva-Datchary, P.; Bäckhed, F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 2016, 165, 1332–1345.
201. Alex, S.; Lange, K.; Amolo, T.; Grinstead, J.S.; Haakonsson, A.K.; Szalowska, E.; Koppen, A.; Mudde, K.; Haenen, D.; Al-Lahham, S.; et al. Short-Chain Fatty Acids Stimulate Angiopoietin-Like 4 Synthesis in Human Colon Adenocarcinoma Cells by Activating Peroxisome Proliferator-Activated Receptor. Mol. Cell. Biol. 2013, 33, 1303–1316.
202. Elamin, E.E.; Masclee, A.A.; Dekker, J.; Pieters, H.-J.; Jonkers, D.M. Short-Chain Fatty Acids Activate AMP-Activated Protein Kinase and Ameliorate Ethanol-Induced Intestinal Barrier Dysfunction in Caco-2 Cell Monolayers. J. Nutr. 2013, 143, 1872–1881.
203. Willemsen, L.E.M.; Koetsier, M.A.; Van Deventer, S.J.H.; Van Tol, E.A.F. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E1 and E2 production by intestinal myofibroblasts. Gut 2003, 52, 1442–1447.
204. Assa, A.; Vong, L.; Pinnell, L.J.; Avitzur, N.; Johnson-Henry, K.C.; Sherman, P.M. Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation. J. Infect. Dis. 2014, 210, 1296–1305.
205. Guttman, J.A.; Li, Y.; Wickham, M.E.; Deng, W.; Vogl, A.W.; Finlay, B.B. Attaching and effacing pathogen-induced tight junction disruption in vivo. Cell. Microbiol. 2006, 8, 634–645.
206. Scheppach, W.; Bartram, H.P.; Richter, F.; Müller, J.G.; Greinwald, K.; Tauschel, H.D.; Gierend, M.; Weber, A.; Hegemann, D.; Kubetzko, W.; et al. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. Dig. Dis. Sci. 1996, 41, 2254–2259.
207. Butzner, J.D.; Parmar, R.; Bell, C.J.; Dalal, V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996, 38, 568–573.
208. Martinez-Guryn, K.; Hubert, N.; Frazier, K.; Urlass, S.; Musch, M.W.; Ojeda, P.; Pierre, J.F.; Miyoshi, J.; Sontag, T.J.; Cham, C.M.; et al. Small Intestine Microbiota Regulate Host Digestive and Absorptive Adaptive Responses to Dietary Lipids. Cell Host Microbe 2018, 23, 458-469.e5.
209. Maciejewska, D.; Skonieczna-Zydecka, K.; Lukomska, A.; Gutowska, I.; Dec, K.; Kupnicka, P.; Palma, J.; Pilutin, A.; Marlicz, W.; Stachowska, E. The short chain fatty acids and lipopolysaccharides status in Sprague-Dawley rats fed with high-fat and high-cholesterol diet. J. Physiol. Pharmacol. 2018, 69.
210. Parada Venegas, D.; De la Fuente, M.K.; Landskron, G.; González, M.J.; Quera, R.; Dijkstra, G.; Harmsen, H.J.M.; Faber, K.N.; Hermoso, M.A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front. Immunol. 2019, 10, 277.
211. Cox, M.A.; Jackson, J.; Stanton, M.; Rojas-Triana, A.; Bober, L.; Laverty, M.; Yang, X.; Zhu, F.; Liu, J.; Wang, S.; et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines. World J. Gastroenterol. 2009, 15, 5549–5557.
212. Thaiss, C.A.; Itav, S.; Rothschild, D.; Meijer, M.T.; Levy, M.; Moresi, C.; Dohnalová, L.; Braverman, S.; Rozin, S.; Malitsky, S.; et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature 2016, 540, 544–551.
213. Fraga, C.G.; Oteiza, P.I. Dietary flavonoids: Role of (−)-epicatechin and related procyanidins in cell signaling. Free Radic. Biol. Med. 2011, 51, 813–823.
214. Rivera, L.; Morón, R.; Sánchez, M.; Zarzuelo, A.; Galisteo, M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity 2008, 16, 2081–2087.
215. Son, M.; Ko, J. Il; Kim, W.B.; Kang, H.K.; Kim, B.K. Taurine Can Ameliorate Inflammatory Bowel Disease in Rats. In Advances in experimental medicine and biology; Springer: Boston, MA,United States, 1998; Vol. 442, pp. 291–298.
216. Chery, J.; Dvoskin, D.; Morato, F.P.; Fahoum, B. Lactobacillus fermentum, a pathogen in documented cholecystitis. Int. J. Surg. Case Rep. 2013, 4, 662–664.
217. Zagato, E.; Mileti, E.; Massimiliano, L.; Fasano, F.; Budelli, A.; Penna, G.; Rescigno, M. Lactobacillus paracasei CBA l74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in Vitro and protective effects against colitis and an enteric pathogen in Vivo. PLoS One 2014, 9, e87615.
218. Jones, S.E.; Versalovic, J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 2009, 9, 35.
219. Bermudez-Brito, M.; Muñoz-Quezada, S.; Gomez-Llorente, C.; Matencio, E.; Bernal, M.J.; Romero, F.; Gil, A. Human Intestinal Dendritic Cells Decrease Cytokine Release against Salmonella Infection in the Presence of Lactobacillus paracasei upon TLR Activation. PLoS One 2012, 7, e43197.
220. Ma, G.; Pan, B.; Chen, Y.; Guo, C.; Zhao, M.; Zheng, L.; Chen, B. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci. Rep. 2017, 37.
221. Preciado, G.M.; Michel, M.M.; Villarreal-Morales, S.L.; Flores-Gallegos, A.C.; Aguirre-Joya, J.; Morlett-Chávez, J.; Aguilar, C.N.; Rodríguez-Herrera, R. Bacteriocins and Its Use for Multidrug-Resistant Bacteria Control. In Antibiotic Resistance; Elsevier, 2016; pp. 329–349 ISBN 9780128036686.
222. Lages, M.C.A.; Beilharz, K.; Morales Angeles, D.; Veening, J.W.; Scheffers, D.J. The localization of key Bacillus subtilis penicillin binding proteins during cell growth is determined by substrate availability. Environ. Microbiol. 2013, 15, 3272–3281.
223. Vilchèze, C.; Hartman, T.; Weinrick, B.; Jacobs, W.R. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat. Commun. 2013, 4, 1881.
224. Tukenmez, U.; Aktas, B.; Aslim, B.; Yavuz, S. The relationship between the structural characteristics of lactobacilli-EPS and its ability to induce apoptosis in colon cancer cells in vitro. Sci. Rep. 2019, 9, 8268.
225. Paulos, C.M.; Wrzesinski, C.; Kaiser, A.; Hinrichs, C.S.; Chieppa, M.; Cassard, L.; Palmer, D.C.; Boni, A.; Muranski, P.; Yu, Z.; et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 2007, 117, 2197–2204.
226. Abotaleb, M.; Samuel, S.; Varghese, E.; Varghese, S.; Kubatka, P.; Liskova, A.; Büsselberg, D. Flavonoids in Cancer and Apoptosis. Cancers (Basel). 2018, 11, 28.
227. Tin, A.S.; Park, A.H.; Sundar, S.N.; Firestone, G.L. Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells. BMC Biol. 2014, 12, 72.
228. Chinni, S.R.; Li, Y.; Upadhyay, S.; Koppolu, P.K.; Sarkar, F.H. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001, 20, 2927–2936.
229. Hashimoto, T.; Perlot, T.; Rehman, A.; Trichereau, J.; Ishiguro, H.; Paolino, M.; Sigl, V.; Hanada, T.; Hanada, R.; Lipinski, S.; et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012, 487, 477–481.
230. Taleb, S. Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases. Front. Immunol. 2019, 10.
231. Clarke, G.; Grenham, S.; Scully, P.; Fitzgerald, P.; Moloney, R.D.; Shanahan, F.; Dinan, T.G.; Cryan, J.F. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol. Psychiatry 2013, 18, 666–673.
232. Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015, 161, 264–276.
233. Smith, E.A.; Macfarlane, G.T. Enumeration of human colonie bacteria producing phenolic and indolic compounds: Effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J. Appl. Bacteriol. 1996, 81, 288–302.
234. Lee, J.-H.; Lee, J. Indole as an intercellular signal in microbial communities. FEMS Microbiol. Rev. 2010, 34, 426–444.
235. Elsden, S.R.; Hilton, M.G.; Waller, J.M. The end products of the metabolism of aromatic amino acids by clostridia. Arch. Microbiol. 1976, 107, 283–288.
236. Devlin, A.S.; Marcobal, A.; Dodd, D.; Nayfach, S.; Plummer, N.; Meyer, T.; Pollard, K.S.; Sonnenburg, J.L.; Fischbach, M.A. Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host Microbe 2016, 20, 709–715.
237. Williams, B.B.; Van Benschoten, A.H.; Cimermancic, P.; Donia, M.S.; Zimmermann, M.; Taketani, M.; Ishihara, A.; Kashyap, P.C.; Fraser, J.S.; Fischbach, M.A. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 2014, 16, 495–503.
238. Dodd, D.; Spitzer, M.H.; Van Treuren, W.; Merrill, B.D.; Hryckowian, A.J.; Higginbottom, S.K.; Le, A.; Cowan, T.M.; Nolan, G.P.; Fischbach, M.A.; et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 2017, 551, 648–652.
239. Wilck, N.; Matus, M.G.; Kearney, S.M.; Olesen, S.W.; Forslund, K.; Bartolomaeus, H.; Haase, S.; Mahler, A.; Balogh, A.; Marko, L.; et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature 2017, 551, 585–589.
240. Russell, W.R.; Duncan, S.H.; Scobbie, L.; Duncan, G.; Cantlay, L.; Calder, A.G.; Anderson, S.E.; Flint, H.J. Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol. Nutr. Food Res. 2013, 57, 523–535.
241. Aragozzini, F.; Ferrari, A.; Pacini, N.; Gualandris, R. Indole-3-lactic acid as a tryptophan metabolite produced by Bifidobacterium spp. Appl. Environ. Microbiol. 1979, 38, 544–546.
242. Sonowal, R.; Swimm, A.; Sahoo, A.; Luo, L.; Matsunaga, Y.; Wu, Z.; Bhingarde, J.A.; Ejzak, E.A.; Ranawade, A.; Qadota, H.; et al. Indoles from commensal bacteria extend healthspan. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, E7506–E7515.
243. Lee, J.-H.; Wood, T.K.; Lee, J. Roles of Indole as an Interspecies and Interkingdom Signaling Molecule. Trends Microbiol. 2015, 23, 707–718.
244. Lee, J.; Jayaraman, A.; Wood, T.K. Indole is an inter-species biofilm signal mediated by SdiA. BMC Microbiol. 2007, 7, 42.
245. Lee, J.; Attila, C.; Cirillo, S.L.G.; Cirillo, J.D.; Wood, T.K. Indole and 7-hydroxyindole diminish Pseudomonas aeruginosa virulence. Microb. Biotechnol. 2009, 2, 75–90.
246. Chu, W.; Zere, T.R.; Weber, M.M.; Wood, T.K.; Whiteley, M.; Hidalgo-Romano, B.; Valenzuela, E.; McLean, R.J.C. Indole production promotes escherichia coli mixed-culture growth with Pseudomonas aeruginosa by inhibiting quorum signaling. Appl. Environ. Microbiol. 2012, 78, 411–419.
247. Nikaido, E.; Giraud, E.; Baucheron, S.; Yamasaki, S.; Wiedemann, A.; Okamoto, K.; Takagi, T.; Yamaguchi, A.; Cloeckaert, A.; Nishino, K. Effects of indole on drug resistance and virulence of Salmonella enterica serovar Typhimurium revealed by genome-wide analyses. Gut Pathog. 2012, 4, 5.
248. Vega, N.M.; Allison, K.R.; Khalil, A.S.; Collins, J.J. Signaling-mediated bacterial persister formation. Nat. Chem. Biol. 2012, 8, 431–433.
249. Hirakawa, H.; Hayashi-Nishino, M.; Yamaguchi, A.; Nishino, K. Indole enhances acid resistance in Escherichia coli. Microb. Pathog. 2010, 49, 90–94.
250. Vega, N.M.; Allison, K.R.; Samuels, A.N.; Klempner, M.S.; Collins, J.J. Salmonella typhimurium intercepts Escherichia coli signaling to enhance antibiotic tolerance. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 14420– 14425.
251. Molina-Santiago, C.; Daddaoua, A.; Fillet, S.; Duque, E.; Ramos, J.L. Interspecies signalling: Pseudomonas putida efflux pump TtgGHI is activated by indole to increase antibiotic resistance. Environ. Microbiol. 2014, 16, 1267–1281. 263. Chimerel, C.; Field, C.M.; Piñero-Fernandez, S.; Keyser, U.F.; Summers, D.K. Indole prevents Escherichia coli cell division by modulating membrane potential. Biochim. Biophys. Acta-Biomembr. 2012, 1818, 1590– 1594.
252. Kim, J.; Hong, H.; Heo, A.; Park, W. Indole toxicity involves the inhibition of adenosine triphosphate production and protein folding in Pseudomonas putida. FEMS Microbiol. Lett. 2013, 343, 89–99.
253. Lee, J.H.; Cho, H.S.; Kim, Y.; Kim, J.A.; Banskota, S.; Cho, M.H.; Lee, J. Indole and 7-benzyloxyindole attenuate the virulence of Staphylococcus aureus. Appl. Microbiol. Biotechnol. 2013, 97, 4543–4552.
254. Plovier, H.; Cani, P.D. Enteroendocrine Cells: Metabolic Relays between Microbes and Their Host. In Endocrine Development; Karger Publishers: Basel, Switzerland, 2017; Vol. 32, pp. 139–164.
255. Levy, M.; Blacher, E.; Elinav, E. Microbiome, metabolites and host immunity. Curr. Opin. Microbiol. 2017, 35, 8–15.
256. Hubbard, T.D.; Murray, I.A.; Perdew, G.H. Special section on drug metabolism and the microbiome-Minireview indole and tryptophan metabolism: Endogenous and dietary routes to ah receptor activation. Drug Metab. Dispos. 2015, 43, 1522–1535.
257. Zhao, H.; Chen, L.; Yang, T.; Feng, Y.-L.; Vaziri, N.D.; Liu, B.-L.; Liu, Q.-Q.; Guo, Y.; Zhao, Y.-Y. Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma. J. Transl. Med. 2019, 17, 302.
258. Stockinger, B.; Meglio, P. Di; Gialitakis, M.; Duarte, J.H. The Aryl Hydrocarbon Receptor: Multitasking in the Immune System. Annu. Rev. Immunol. 2014, 32, 403–432.
259. Gutiérrez-Vázquez, C.; Quintana, F.J. Regulation of the Immune Response by the Aryl Hydrocarbon Receptor. Immunity 2018.
260. Stejskalova, L.; Dvorak, Z.; Pavek, P. Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art. Curr. Drug Metab. 2011, 12, 198–212.
261. Su, H.-H.; Lin, H.-T.; Suen, J.-L.; Sheu, C.C.; Yokoyama, K.K.; Huang, S.-K.; Cheng, C.M. Aryl hydrocarbon receptor-ligand axis mediates pulmonary fibroblast migration and differentiation through increased arachidonic acid metabolism. Toxicology 2016, 370, 116–126.
262. Chiaro, C.R.; Patel, R.D.; Perdew, G.H. 12(R)-hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor. Mol. Pharmacol. 2008, 74, 1649–1656.
263. Quintana, F.J.; Sherr, D.H. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol. Rev. 2013, 65, 1148–1161.
264. Kerkvliet, N.I.; Shepherd, D.M.; Baecher-Steppan, L. T lymphocytes are direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD. Toxicol. Appl. Pharmacol. 2002, 185, 146–152.
265. Singh, N.P.; Singh, U.P.; Rouse, M.; Zhang, J.; Chatterjee, S.; Nagarkatti, P.S.; Nagarkatti, M. Dietary Indoles Suppress Delayed-Type Hypersensitivity by Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T Cells through Regulation of MicroRNA. J. Immunol. 2016, 196, 1108– 1122.
266. Mezrich, J.D.; Fechner, J.H.; Zhang, X.; Johnson, B.P.; Burlingham, W.J.; Bradfield, C.A. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells. J. Immunol. 2010, 185, 3190–3198.
267. Veldhoen, M.; Hirota, K.; Westendorf, A.M.; Buer, J.; Dumoutier, L.; Renauld, J.C.; Stockinger, B. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453, 106–109.
268. Kimura, A.; Naka, T.; Nohara, K.; Fujii-Kuriyama, Y.; Kishimoto, T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 9721–9726.
269. Cui, G.; Qin, X.; Wu, L.; Zhang, Y.; Sheng, X.; Yu, Q.; Sheng, H.; Xi, B.; Zhang, J.Z.; Zang, Y.Q. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J. Clin. Invest. 2011, 121, 658–670.
270. Quintana, F.J.; Basso, A.S.; Iglesias, A.H.; Korn, T.; Farez, M.F.; Bettelli, E.; Caccamo, M.; Oukka, M.; Weiner, H.L. Control of Treg and Th17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453, 65–71.
271. Zhang, L.; Ma, J.; Takeuchi, M.; Usui, Y.; Hattori, T.; Okunuki, Y.; Yamakawa, N.; Kezuka, T.; Kuroda, M.; Goto, H. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor. Investig. Ophthalmol. Vis. Sci. 2010, 51, 2109–2117.
272. Benson, J.M.; Shepherd, D.M. Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn’s disease. Toxicol. Sci. 2011, 120, 68–78.
273. Singh, N.P.; Singh, U.P.; Singh, B.; Price, R.L.; Nagarkatti, M.; Nagarkatti, P.S. Activation of Aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of Foxp3 and IL-17 expression and amelioration of experimental colitis. PLoS One 2011, 6, e23522.
274. Kerkvliet, N.I.; Steppan, L.B.; Vorachek, W.; Oda, S.; Farrer, D.; Wong, C.P.; Pham, D.; Mourich, D. V. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3 + T cells in pancreatic lymph nodes. Immunotherapy 2009, 1, 539–547.
275. Lanis, J.M.; Alexeev, E.E.; Curtis, V.F.; Kitzenberg, D.A.; Kao, D.J.; Battista, K.D.; Gerich, M.E.; Glover, L.E.; Kominsky, D.J.; Colgan, S.P. Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia. Mucosal Immunol. 2017, 10, 1133–1144.
276. Lamas, B.; Richard, M.L.; Leducq, V.; Pham, H.P.; Michel, M.L.; Da Costa, G.; Bridonneau, C.; Jegou, S.; Hoffmann, T.W.; Natividad, J.M.; et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 2016, 22, 598–605.
277. Monteleone, I.; Rizzo, A.; Sarra, M.; Sica, G.; Sileri, P.; Biancone, L.; MacDonald, T.T.; Pallone, F.; Monteleone, G. Aryl Hydrocarbon Receptor-Induced Signals Up-regulate IL-22 Production and Inhibit Inflammation in the Gastrointestinal Tract. Gastroenterology 2011, 141, 237-248.e1.
278. Lin, L.; Tan, B.; Pantapalangkoor, P.; Ho, T.; Baquir, B.; Tomaras, A.; Montgomery, J.I.; Reilly, U.; Barbacci, E.G.; Hujer, K.; et al. Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis. MBio 2012, 3.
279. Hauser, A.R.; Mecsas, J.; Moir, D.T. Beyond antibiotics: New therapeutic approaches for bacterial infections. Clin. Infect. Dis. 2016, 63, 89–95. 292. Jiang, Q.; Chen, J.; Yang, C.; Yin, Y.; Yao, K. Quorum Sensing: A Prospective Therapeutic Target for Bacterial Diseases. Biomed Res. Int. 2019, 2019, 1–15. 293. Metidji, A.; Omenetti, S.; Crotta, S.; Li, Y.; Nye, E.; Ross, E.; Li, V.; Maradana, M.R.; Schiering, C.; Stockinger, B. The Environmental Sensor AHR Protects from Inflammatory Damage by Maintaining Intestinal Stem Cell Homeostasis and Barrier Integrity. Immunity 2018, 49, 353-362.e5.
280. Natividad, J.M.; Agus, A.; Planchais, J.; Lamas, B.; Jarry, A.C.; Martin, R.; Michel, M.L.; Chong-Nguyen, C.; Roussel, R.; Straube, M.; et al. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. Cell Metab. 2018, 28, 737-749.e4.
281. Lanktree, M.B.; Hegele, R.A. Metabolic Syndrome. In Genomic and Precision Medicine; Elsevier, 2017; pp. 283–299 ISBN 9780128006542.
282. Romani, L.; Puccetti, P.; Zelante, T.; Ricci, M.; Giovagnoli, S. Indole-3-aldehyde for treating immune dysreactive diseases. European Patent EP3035967B1, 18 December 2019.
283. Puccetti, M.; Giovagnoli, S.; Zelante, T.; Romani, L.; Ricci, M. Development of Novel Indole-3-Aldehyde– Loaded Gastro-Resistant Spray-Dried Microparticles for Postbiotic Small Intestine Local Delivery. J. Pharm. Sci. 2018, 107, 2341–2353.
284. Guo, X.; Qiu, J.; Tu, T.; Yang, X.; Deng, L.; Anders, R.A.; Zhou, L.; Fu, Y.X. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity 2014, 40, 25–39.
285. Swimm, A.; Giver, C.R.; DeFilipp, Z.; Rangaraju, S.; Sharma, A.; Antonova, A.U.; Sonowal, R.; Capaldo, C.; Powell, D.; Qayed, M.; et al. Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. Blood 2018, 132, 2506–2519.
286. Yu, J.; Luo, Y.; Zhu, Z.; Zhou, Y.; Sun, L.; Gao, J.; Sun, J.; Wang, G.; Yao, X.; Li, W. A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor. J. Allergy Clin. Immunol. 2019, 143, 2108-2119.e12.
287. Bommarius, B.; Anyanful, A.; Izrayelit, Y.; Bhatt, S.; Cartwright, E.; Wang, W.; Swimm, A.I.; Benian, G.M.; Schroeder, F.C.; Kalman, D. A Family of Indoles Regulate Virulence and Shiga Toxin Production in Pathogenic E. coli. PLoS One 2013, 8, e54456.
288. Romani, L.; Zelante, T.; Luca, A. De; Iannitti, R.G.; Moretti, S.; Bartoli, A.; Aversa, F.; Puccetti, P. Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi. Eur. J. Immunol. 2014, 44, 3192–3200.
289. Cicenia, A.; Scirocco, A.; Carabotti, M.; Pallotta, L.; Marignani, M.; Severi, C. Postbiotic Activities of Lactobacilli-derived Factors. J. Clin. Gastroenterol. 2014, 48, S18–S22.
290. Clayton, T.A.; Lindon, J.C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J.P.; Net, J.L. Le; Baker, D.; Walley, R.J.; et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440, 1073–1077.
291. Holmes, E.; Kinross, J.; Gibson, G.R.; Burcelin, R.; Jia, W.; Pettersson, S.; Nicholson, J.K. Therapeutic Modulation of Microbiota-Host Metabolic Interactions. Sci. Transl. Med. 2012, 4, 137rv6-137rv6.
292. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science 2012, 336, 1262–7.